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Development/Plasticity/Repair

Reversal of Aging-Related Neuronal Ca2⫹ Dysregulation and
Cognitive Impairment by Delivery of a Transgene Encoding
FK506-Binding Protein 12.6/1b to the Hippocampus
John C. Gant,1 Kuey-Chu Chen,1 Inga Kadish,2 Eric M. Blalock,1 Olivier Thibault,1 Nada M. Porter,1
and Philip W. Landfield1
1

Department of Pharmacology and Nutritional Sciences, University of Kentucky, Lexington, Kentucky 40536 and 2Department of Cell, Developmental, and
Integrative Biology, University of Alabama at Birmingham, Birmingham, Alabama 35294

Brain Ca 2⫹ regulatory processes are altered during aging, disrupting neuronal, and cognitive functions. In hippocampal pyramidal
neurons, the Ca 2⫹-dependent slow afterhyperpolarization (sAHP) exhibits an increase with aging, which correlates with memory impairment. The increased sAHP results from elevated L-type Ca 2⫹ channel activity and ryanodine receptor (RyR)-mediated Ca 2⫹ release,
but underlying molecular mechanisms are poorly understood. Previously, we found that expression of the gene encoding FK506-binding
protein 12.6/1b (FKBP1b), a small immunophilin that stabilizes RyR-mediated Ca 2⫹ release in cardiomyocytes, declines in hippocampus
of aged rats and Alzheimer’s disease subjects. Additionally, knockdown/disruption of hippocampal FKBP1b in young rats augments neuronal
Ca 2⫹ responses. Here, we test the hypothesis that declining FKBP1b underlies aging-related hippocampal Ca 2⫹ dysregulation. Using microinjection of adeno-associated viral vector bearing a transgene encoding FKBP1b into the hippocampus of aged male rats, we assessed the critical
prediction that overexpressing FKBP1b should reverse Ca 2⫹-mediated manifestations of brain aging. Immunohistochemistry and qRT-PCR
confirmedhippocampalFKBP1boverexpression4 – 6weeksafterinjection.Comparedtoagedvectorcontrols,agedratsoverexpressingFKBP1b
showed dramatic enhancement of spatial memory, which correlated with marked reduction of sAHP magnitude. Furthermore, simultaneous
electrophysiological recording and Ca 2⫹ imaging in hippocampal neurons revealed that the sAHP reduction was associated with a decrease in
parallel RyR-mediated Ca 2⫹ transients. Thus, hippocampal FKBP1b overexpression reversed key aspects of Ca 2⫹ dysregulation and cognitive
impairment in aging rats, supporting the novel hypothesis that declining FKBP1b is a molecular mechanism underlying aging-related Ca 2⫹
dysregulation and unhealthy brain aging and pointing to FKBP1b as a potential therapeutic target.
Key words: Alzheimer’s disease; aging; calcium; FKBP; memory; ryanodine receptor

Significance Statement
This paper reports critical tests of a novel hypothesis that proposes a molecular mechanism of unhealthy brain aging and possibly,
Alzheimer’s disease. For more than 30 years, evidence has been accumulating that brain aging is associated with dysregulation of
calcium in neurons. Recently, we found that FK506-binding protein 12.6/1b (FKBP1b), a small protein that regulates calcium,
declines with aging in the hippocampus, a brain region important for memory. Here we used gene therapy approaches and found
that raising FKBP1b reversed calcium dysregulation and memory impairment in aging rats, allowing them to perform a memory
task as well as young rats. These studies identify a potential molecular mechanism of brain aging and may also have implications
for treatment of Alzheimer’s disease.

Introduction
The population of developed nations is projected to age significantly over the next several decades. Because advanced age is the
leading risk factor for Alzheimer’s disease (AD) and other cogniReceived March 31, 2015; revised June 15, 2015; accepted June 23, 2015.
Author contributions: J.C.G., K.-C.C., and P.W.L. designed research; J.C.G., K.-C.C., and I.K. performed research;
J.C.G. and E.M.B. analyzed data; J.C.G., K.-C.C., E.M.B., O.T., N.M.P., and P.W.L. wrote the paper.
This work was supported by Grant R37-AG004542 from the National Institute on Aging.
This article is freely available online through the J Neurosci Author Open Choice option.

tive disorders, a corollary of this increase in population age will be
a substantial rise in the prevalence of cognitively impaired individuals and a resulting enormous socioeconomic burden (Reitz
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Creative Commons Attribution 4.0 International, whichpermitsunrestricteduse,distributionandreproductioninany
medium provided that the original work is properly attributed.
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et al., 2011; Hebert et al., 2013). Discovery of new therapeutic
approaches that can delay cognitive impairment would significantly mitigate this burden, but such discovery will likely be difficult without improved understanding of the molecular
mechanisms underlying unhealthy brain aging and aging-related
susceptibility to Alzheimer’s disease. In this regard, accumulating
evidence suggests that mechanisms of deleterious brain aging can
be elucidated in part by investigation of the molecular machinery
regulating neuronal Ca 2⫹ homeostasis.
Numerous studies have found that Ca 2⫹-dependent neuronal
processes are dysregulated during brain aging, generally in a cell
type- and region-specific manner (Gibson and Peterson, 1987;
Landfield, 1987; Khachaturian, 1989; Disterhoft et al., 1996; Foster and Norris, 1997; Lynch et al., 2006; Murchison and Griffith,
2007; Thibault et al., 2007; Toescu and Verkhratsky, 2007). In
CA1 pyramidal neurons of the dorsal hippocampus, a region
important for learning and memory (Moser et al., 1995; Buzsáki
and Moser, 2013), one of the most consistent manifestations of
aging is an increased magnitude of the Ca 2⫹-dependent, K ⫹mediated slow afterhyperpolarization (sAHP; Landfield and
Pitler, 1984; Moyer et al., 1992; Disterhoft and Oh, 2006; Gant et
al., 2006). The sAHP is generated by hyperpolarizing Ca 2⫹-sensitive
K ⫹ channels that are activated by action potential-induced Ca 2⫹
influx and resulting Ca 2⫹ release from intracellular ryanodine receptors (RyRs; Madison and Nicoll, 1984; Sah and Bekkers, 1996;
Lancaster et al., 2001; Andrade et al., 2012). The aging-related increases in the hippocampal sAHP and other Ca 2⫹-mediated processes, which act to dampen neuronal excitability, have been
found to correlate with impaired learning in several species (Disterhoft et al., 1996; Thibault and Landfield, 1996; Tombaugh et
al., 2005; Luebke and Amatrudo, 2012), suggesting that the
mechanisms underlying Ca 2⫹ dysregulation may be directly relevant to brain dysfunction with aging. Although aging-related
augmentation of the hippocampal sAHP appears to be driven
primarily by elevations in voltage-gated L-type Ca 2⫹ channel
(LTCC) activity (Moyer et al., 1992; Disterhoft et al., 1996; Thibault and Landfield, 1996; Murphy et al., 2006) and Ca 2⫹induced Ca 2⫹ release (CICR) from intracellular RyRs (Kumar
and Foster, 2005; Gant et al., 2006; Thibault et al., 2007), the
elevated activity is not associated with upregulation of LTCC
expression (Rowe et al., 2007). Thus, the molecular bases for
these increases in Ca 2⫹ sources remain unclear.
However, in microarray studies of gene expression in the rat
hippocampus (Kadish et al., 2009), we found aging-related
downregulation of the gene encoding FK506-binding protein
12.6/1b (FKBP1b), a small immunophilin that inhibits Ca 2⫹ release from sarcoplasmic reticulum RyRs in cardiomyocytes (Zalk
et al., 2007). Moreover, in electrophysiological and Ca 2⫹ imaging
studies, we found that knockdown/disruption of FKBP1b in rat
hippocampal neurons augments Ca 2⫹ transients generated by
RyR-mediated Ca 2⫹ release or LTCC activation (Gant et al.,
2011). Those findings suggest the hypothesis that aging-related
decline or dysfunction of FKBP1b is a molecular mechanism of
hippocampal Ca 2⫹ dyshomeostasis and consequent cognitive
impairment. Here, using viral-mediated delivery of a transgene
encoding FKBP1b, we tested a key prediction of this hypothesis,
namely, that selectively counteracting the FKBP1b deficit in aged
hippocampus should reduce/reverse Ca 2⫹ dysregulation and impaired cognition. The results clearly show that overexpressing
FKBP1b in hippocampal neurons is sufficient to reverse major
manifestations of Ca 2⫹-mediated brain aging.
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Materials and Methods
Animals. Young mature (4 –5 months old) and aged (20 –22 months old)
male Fischer 344 (F344) rats were obtained from the aging rodent colony
maintained by the National Institute on Aging. The present study comprises experiments using four cohorts of F344 male rats. The size, composition, treatments, and measures used for each cohort are described in
the corresponding Results section. All protocols and procedures were
performed in accordance with institutional guidelines and were approved by the Animal Care and Use Committee.
Adeno-associated viral vector constructs and microinjection. We induced
FKBP1b overexpression in the hippocampus of male F344 rats using
one-time microinjection of a recombinant adeno-associated viral (AAV)
vector construct containing the transgene for rat FKBP1b under the control of the largely neuron-specific Ca 2⫹-calmodulin kinase II (CaMKII)
promoter. Because of their safety, efficacy, and long-lasting effects, AAV
vector approaches are widely used for brain gene transfer studies in animal models and humans (Broekman et al., 2006; Kaplitt et al., 2007;
McCown, 2010; Salegio et al., 2012; Bosch et al., 2014). Before the
FKBP1b overexpression experiments, we used a reporter gene, enhanced
green florescent protein (EGFP), and the FKBP1b transgene to conduct
extensive pilot studies and compare transduction efficiency, tropism,
and expression of three AAV serotypes (1, 8, and 9) and three promoters
(CB7, CaMKII, and Synapsin) under our specific experimental conditions. These serotypes have been shown to exhibit high transduction
efficiency in principal neurons of the brain (Broekman et al., 2006; Aschauer et al., 2013; Bosch et al., 2014), and in our studies all three serotypes showed good in vivo transduction of hippocampal pyramidal
neurons in adult rats 4 – 6 weeks after microinjection into the hippocampus (see Results, below). For the FKBP1b overexpression experiments,
we selected AAV serotype 9 and the CaMKII promoter, as this combination exhibited slightly higher transduction and expression in pyramidal
neurons of the dorsal hippocampus with minimal spread beyond the
ipsilateral hippocampus. Vectors were delivered via microsyringe under
stereotaxic guidance to the apical dendrites (stratum radiatum), below
the mediolateral peak of the CA1 pyramidal cell body layer (stratum
pyramidale) in dorsal hippocampus. Under isoflurane anesthesia, the
microsyringe tip was stereotaxically guided to the target coordinates in
CA1 stratum radiatum (3.8 mm caudal, 2.8 mm lateral from bregma, and
1.7–1.8 mm ventral from the top of the cortex). For each injection, 2 l of
AAV vector were infused into the hippocampus at a rate of 0.2 l/min
using a 10 l Hamilton syringe with a custom 30 gauge needle (Hamilton
Company) and a Stoelting QSI microinjection pump. Following surgery,
animals were treated with analgesics and monitored closely under the
supervision of veterinary staff. The design of the AAV-FKBP1b vector
was AAV2/9.CAMKII0.4.ratFKBP1b.rBG (titer, 1.99e13 genome copies
per milliliter (GC/ml) or 1.99e12 GC/ml). The design of the AAV-EGFP
control vector was the same except that the EGFP transgene was substituted for the FKBP1b transgene: AAV2/9.CAMKII0.4.EGFP.rBG (titer,
1.86e13 GC/ml). AAV vectors were constructed and amplified by the
Penn Vector Core (Philadelphia, PA).
Morris water maze test of spatial memory. Cognitive function was tested
using the Morris water maze (MWM), with procedures similar to those
described previously (Rowe et al., 2007; Kadish et al., 2009). Multiple
groups have found deficient spatial learning in the MWM to be a highly
sensitive and reliable index of aging-related cognitive impairment in
rodents (Gallagher and Rapp, 1997; Markowska, 1999; Tombaugh et al.,
2005; Kadish et al., 2009). The MWM used here consisted of a 190-cmdiameter black round tub filled with water (26°C). A 15-cm-diameter
escape platform was placed in one of four pool quadrants 1 cm below the
water surface and remained in this position until the memory retention
probe trial, during which it was removed. The pool was surrounded by
circular black curtains with three high-contrast geometric images hung
on the inner side of the curtains. Tracking was achieved through contrast
imaging using water maze acquisition software (Columbus Instruments). The spatial learning protocol consisted of 4 d of training (learning phase) followed by a memory retention probe trial on the fifth day
and a visual acuity/motor function test (cued trial, sixth day). On each
training day, subjects were given three trials in which they were placed
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into the pool from a different quadrant location on each trial and allowed
up to 60 s to find and climb onto the escape platform. After a rat found
the platform, it was left on the platform for an additional 30 s. Those
animals that did not find the platform were gently guided to the platform
and allowed to remain there for 30 s before being returned to their cage.
Intertrial interval was 2 min. On the fifth day (retention test probe), the
platform was removed, and the subjects were placed into the pool from a
different location and allowed to swim for 60 s. On the sixth day, a cued
trial was performed with a white contrasting marker placed 6 inches
above the platform location. Performance on all trials was assessed by
path length and latency to reach the platform or former location of the
platform.
For the maze learning experiment, 15 aged rats (20 months old) received bilateral injections of AAV-FKBP1b, 7 rats at the original titer
(1.99e13 GC/ml) and 8 rats at a 10-fold lower titer (1.99e12 GC/ml), and
10 aged control animals received bilateral injections of AAV-EGFP
(1.86e13 GC/ml). Ten young control rats received bilateral injections of
AAV-EGFP (1.86e13 GC/ml, n ⫽ 5) or bilateral sham surgeries (n ⫽ 5) in
which the microsyringe was lowered into the hippocampus, but no injection administered. Because the two AAV-FKBP1b titer subgroups did
not differ on any performance measure, they were combined into a single
group, Aged-FKBP1b, for the statistical analyses. Similarly, the young
control EGFP and young control sham subgroups did not differ from one
another on any measure and were treated statistically as a single group,
Young-Control.
Intracellular recording in hippocampal slice pyramidal neurons. Our
sharp-electrode electrophysiological methods have been described previously (Thibault et al., 2001; Gant et al., 2006, 2011). Briefly, rats were
anesthetized in a CO2 chamber before rapid decapitation. Intracellular
recordings were obtained from CA1 pyramidal neuron cell bodies in
350-m-thick dorsal hippocampal transverse slices maintained in oxygenated artificial CSF [containing (in mM) 128 NaCl, 1.25 KH2PO4, 10
glucose, 26 NaHCO3, 3 KCl, 2 CaCl2, and 2 MgCl2] using sharp glass
pipettes filled with HEPES (10 mM) and KMeSO4 (2 M). Electrophysiological data were acquired and analyzed using pClamp 8, a sharpelectrode amplifier in current-clamp mode (Axoclamp 2B; Molecular
Devices), and a DigiData 1320 board (Molecular Devices). Voltage records were digitized at 2–20 kHz and low-pass filtered at 1 kHz. The
sAHPs were triggered at 0.1 Hz by depolarizing current injection steps
(200 ms duration) set at an intensity in each cell that consistently elicited
a burst of four action potentials. The amplitude of the sAHP was measured at 800 ms following the end of the depolarizing step, and sAHP
duration was determined as the interval from the end of the current step
to the time point at which the membrane potential returned to prestimulus baseline. The integrated area under the curve (AUC; millivolts by
milliseconds) of the sAHP was determined following stimulating current
termination.
Ca2⫹ imaging. Intracellular Ca 2⫹ responses were recorded simultaneously with electrophysiological responses in neurons from a separate
cohort of10 aged rats injected with AAV-FKBP1b in the right (ipsilateral)
hippocampus and with AAV-EGFP in the contralateral hippocampus.
Imaging methods used were similar to those described previously by
several groups, including ours (Magee and Johnston, 1997; Thibault et
al., 2001; Hemond and Jaffe, 2005; Gant et al., 2011; Oh et al., 2013).
Individual hippocampal slice neurons were impaled with sharp pipettes
containing the single-wavelength Ca 2⫹ indicator Calcium Orange (5
mM). Pyramidal neurons with acceptable baseline electrophysiological
characteristics (Table 1) that were also sufficiently close to the slice surface to permit simultaneous visualization of Ca 2⫹ responses (9 AAVFKBP1b- and 6 AAV-EGFP-treated neurons) were imaged on the stage of
a Nikon E600 microscope equipped with a 40⫻ water-immersion objective and a CCD camera (Princeton Instruments). Calcium Orange was
allowed to diffuse into the cell for at least 10 min before Ca 2⫹ fluorescence measures were obtained. Calcium Orange was excited using a
wavelength switcher (Lambda DG-4; Sutter Instrument Company) and
software control (Axon Imaging Workbench; Molecular Devices, version
2.2.1.54). The 575 nm wavelength was monitored through a dichroic
mirror centered at 570 nm during excitation with the 550 nm wavelength. The Ca 2⫹ response elicited during activation of the sAHP was
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Table 1. Baseline electrophysiological measures for neurons from behaviorally
characterized rats (means ⴞ SEM)
Aged-FKBP1b

Aged-Control

Young

F
p
value value

N animals
7
6
5
n neurons
17
16
13
Resting potential (mV) ⫺59.88 ⫾ 0.74 ⫺59.44 ⫾ 0.75 ⫺59.39 ⫾ 0.70 0.14 0.87
Input resistance (M⍀) 56.29 ⫾ 2.02 53.81 ⫾ 2.65 53.85 ⫾ 3.92 0.27 0.76
AP height (mV)
83.91 ⫾ 1.34 86.28 ⫾ 1.47 87.94 ⫾ 2.24 1.50 0.24

recorded in each neuron simultaneously with electrophysiological recordings of the sAHP. In addition, in each cell we recorded the Ca 2⫹
response elicited by 10 s of 7 Hz repetitive synaptic stimulation (RSS)
delivered via a bipolar stimulating electrode on the Schaffer collaterals,
which synapse on CA1 pyramidal cells. Stimulation intensity during RSS
was set at action potential threshold, which at 7 Hz generates an action
potential on essentially each pulse (Thibault et al., 2001). The rise time of
this RSS-induced Ca 2⫹ response is markedly accelerated with aging because of increased RYR-mediated Ca 2⫹ release (Gant et al., 2006). Ca 2⫹
responses were measured in the visible outline of the cell soma, excluding
surrounding low-intensity diffracted light. Following background subtraction from an area devoid of cells, the percentage change in fluorescence during RSS was determined relative to baseline (%⌬F/F ). The
AUC (percentage of fluorescence change times seconds) of the Ca 2⫹
response was determined for the first 5 s of the sAHP-associated Ca 2⫹
responses and the first 5 s of the RSS-generated responses. The RSSinduced Ca 2⫹ levels during the rise to peak Ca 2⫹ concentration were fit
with an exponential curve (confidence interval, ⬎93%) to calculate the
rising time constant (, time to ⬃63.7% of the peak) for each cell.
Quantitative real-time polymerase chain reaction. mRNA amplification
was performed as described previously (Gant et al., 2011) using an ABI prism
7700 sequence detection system (Applied Biosystems) and Taqman One
Step RT-PCR reagents (Applied Biosystems). All samples were run in duplicate in a final volume of 30 l containing 50 ng of cellular RNA and a
Taqman probe (5 M) and primers (10 nM each), with an amplicon spanning
the rat Fkbp1b cDNA region from nucleotides 155 to 259. Cycling parameters for all assays were as follows: 30 min at 48°C, 10 min at 95°C, followed by
40 cycles of 15 s at 95°C and 1 min at 60°C. Primers were designed using
Primer Express software (version 1.5, Applied Biosystems) and chemically
synthesized by Applied Biosystems (forward primer, 5⬘-GCAAGCAGGA
AGTCATCAAAGG-3⬘; reverse primer, 5⬘-CAGTAGCTCCATATGCCACATCA-3⬘; Taqman probe, 5⬘-AGCTCATCTGGGCAGCGCCTTCTT3⬘). The RNA levels of glyceraldehyde-3-phosphate dehydrogenase (Gapdh)
were used as normalization controls for Fkbp1b RNA quantification. Reported values (Fig. 1C) are log10 transforms of the Fkbp1b/Gapdh ratio.
Immunohistochemistry. Our immunohistochemistry (IHC) methods
have been described previously (Kadish et al., 2009). Animals were
deeply anesthetized with sodium pentobarbital (100 mg/kg, i.p.) and
perfused transcardially with cold saline. Brains were placed in 4% paraformaldehyde overnight and then transferred to 15% sucrose for cryoprotection. Before staining, 30-m-thick sections were rinsed in TBS-T
and incubated in the primary FKBP1b antibody (1:500; sc-98742; Santa
Cruz Biotechnology) at room temperature for 18 h. The tissues were
rinsed and incubated with appropriate secondary antibody for 2 h at
room temperature, followed by incubation for 2 h in avidin-peroxidase.
Staining was visualized using a metal-enhanced diaminobenzidine
(DAB) solution. For tissue from animals receiving AAV-EGFP injections, 30 m sections were mounted directly on slides and coverslipped.
Imaging was performed using a Nikon Eclipse TE200 and CRi Nuance
Multispectral Imaging System (Cambridge Research and Instrumentation). A wavelength of 480 nM was used to visualize EGFP. Gray scale
analysis of DAB immunoreactivity was accomplished using Scion software and reported as optical density (average gray value/pixel).
Statistical analysis. Data analyses were performed with Clampfit8 (Molecular Devices) or Sigma Plot (Systat Software), and statistical analyses
performed with StatView (SAS Institute). Multigroup results were analyzed using ANOVA across all groups. Fisher’s protected least significant
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rons cannot be excluded. In another group of six aging rats,
FKBP1b overexpression 5– 6 weeks following delivery of the
transgene was confirmed by qRT-PCR analyses in dorsal hippocampal tissue. These analyses showed a significant increase in
Fkbp1b mRNA expression in the hippocampus injected with
AAV-FKBP1b compared with the contralateral control hippocampus ( p ⬍ 0.05, paired t test; Fig. 1C).
In hippocampal pyramidal cells, the sAHP is generated largely
in the proximal dendrites (Andreasen and Lambert, 1995; Sah
and Bekkers, 1996; Lancaster et al., 2001) and possibly the cell
bodies (Lima and Marrion, 2007). To confirm that FKBP1b expression declines with aging and is rescued by AAV-FKBP1b
transduction in the hippocampal CA1 neurons, we measured
FKBP1b immunostaining optical density in the CA1 neuronal
cell body layer of a separate cohort of 16 rats (five Young-Control
rats, five Aged-Control rats, six Aged-FKBP1b rats). Effects of
AAV-FKBP1b microinjection on FKBP1b expression in stratum
pyramidale were visibly apparent (Figs. 2A–C), and semiquantitative optical density analyses revealed a main effect of age/treatment group (F(2,12) ⫽ 4.24; p ⬍ 0.05). Post hoc comparisons
showed that density of FKBP1b immunostaining was significantly lower ( p ⬍ 0.05) in Aged-Control (134.30 ⫾ 4.29; n ⫽ 5)
relative to Young-Control (150.90 ⫾ 3.58; n ⫽ 5) or AAVFKBP1b-treated aged animals (Aged-FKBP1b; 150.40 ⫾ 4.64;
n ⫽ 6).

Figure 1. Hippocampal expression of EGFP and FKBP1b following microinjection of AAV
vectors harboring the encoding transgenes. A, AAV-EGFP microinjection into field CA1 of dorsal
hippocampus resulted in extensive EGFP expression (green fluorescence) in CA1 pyramidal cell
bodies of the stratum pyramidale. Inset, Higher magnification of CA1 pyramidal cell bodies and
dendrites expressing EGFP. B, FKBP1b immunostaining in AAV-EGFP control (left) and AAVFKBP1b-injected (right) hippocampi, showing more intense immunostaining in the FKBP1b
hippocampus, particularly in CA1 pyramidal cell bodies of the stratum pyramidale (sp, arrow). C,
qRT-PCR measures of Fkbp1b mRNA expression normalized to Gapdh mRNA. Shown is a comparison of right (FKBP1b) versus the left (control) hippocampus of aging rats (n ⫽ 6) 4 –5 weeks
following injection of AAV-FKBP1b into right hippocampus of each animal. *p ⬍ 0.05 (paired t
test).
difference test was used for post hoc group comparisons. Correlations
were calculated using the Pearson product-moment correlation coefficient. P values ⬍0.05 were considered significant. All results are expressed as mean ⫾ SEM.

Results
Localization of overexpression
We performed extensive pilot studies with unilateral injection of
AAV-EGFP or AAV-FKBP1b into the hippocampal field CA1.
Fluorescence microscopy of EGFP and immunostaining of
FKBP1b showed that by 4 – 6 weeks after injection, there was
pronounced expression of EGFP (Fig. 1A) or FKBP1b ( B) in
stratum pyramidale neuronal cell bodies of the CA1, CA2, and, to
a lesser extent, CA3 fields of the ipsilateral dorsal hippocampus.
Expression was less intense in dendrites. The AAV vectors did not
significantly transduce cells in the contralateral hippocampus.
Granule cells in the dentate gyrus were also often transduced (Fig.
1A), likely because of AAV retrograde/anterograde spread along
axonal pathways such as the mossy fibers (Cearley and Wolfe,
2006; Betley and Sternson, 2011; Castle et al., 2014). Consequently, although FKBP1b expression in the hippocampus appears to underlie the behavioral effects reported below,
contributions from hippocampal cell types other than CA1 neu-

Cognitive performance
To test whether overexpression of FKBP1b could reverse established indicators of aging-related cognitive decline, we assessed
MWM spatial memory in another cohort of young and aged F344
rats (n ⫽ 35 animals total). Aged animals were divided into two
groups: the Aged-Control group (n ⫽ 10) received bilateral injections of AAV-EGFP, and Aged-FKBP1b rats (n ⫽ 15) received
bilateral injections of AAV-FKBP1b. Additionally, a YoungControl group (n ⫽ 10; five bilateral EGFP plus five bilateral
Sham) was included to determine the normal young baseline
under our conditions. Behavioral testing was initiated 5– 6 weeks
after bilateral AAV injections. Animals were given 4 d of training
(three trials per day) to learn the fixed location of a submerged
escape platform. The platform was removed on the fifth day, and
animals were tested for memory (retention probe trial) of the
platform’s former location. On the sixth day (cued trial), sensorimotor function was evaluated in a trial during which the platform’s location was visually cued. All groups exhibited a
significant improvement in water maze performance over the 4 d
course of training (Fig. 3A), as reflected in main effects across
trials (repeated measures ANOVA across all trials) for latency and
path length to platform location (F(11,352) ⫽ 16.74, p ⬍ 0.0001
and F(11,352) ⫽ 6.28, p ⬍ 0.01, respectively; for illustrative clarity,
only path length values are shown in Figure 3A). No consistent
group differences were seen across training, although by the last
training day there was a trend for the Young-Control and
Aged-FKBP1b groups to outperform the Aged-Control group
(Fig. 3A).
The memory retention probe trial, performed 24 h after the
last training session (Day 5), revealed a highly significant main
effect of treatment group on both path length and latency to the
platform’s former location (F(2,32) ⫽ 11.15, p ⬍ 0.001 and F(2,32)
⫽ 4.92, p ⬍ 0.01 respectively). Post hoc analyses showed that the
Aged-FKBP1b group and the Young-Control group both performed significantly better than the Aged-Control group on path
length and latency to platform ( p ⬍ 0.001 and p ⬍ 0.01, respectively; Fig. 3B), but did not differ from each other. No group

10882 • J. Neurosci., July 29, 2015 • 35(30):10878 –10887

Gant et al. • Reversal of Hippocampal Aging by FKBP 12.6/1b

Figure 2. Aging-related decline in FKBP1b expression in CA1 pyramidal cell bodies is counteracted by AAV-mediated FKBP1b overexpression. A–C, Representative examples of FKBP1b
immunostaining in the CA1 pyramidal cell body layer (stratum pyramidale) of Young-Control
(A), Aged-Control (B), and AAV-FKBP1b-treated (C) rats, illustrating age-related decline of
FKBP1b expression and rescue in aged rats by AAV-FKBP1b microinjection. sp, Stratum pyramidale; sr, stratum radiatum.

differences were found in the cued test (Day 6). All groups performed at a high level (Fig. 3C), indicating that aging-related
sensorimotor deficits did not account for the differences in
MWM retention performance.
Effects of FKBP1b overexpression on the Ca 2ⴙ-dependent
sAHP
We then determined whether the AAV-FKBP1b intervention also
reversed age-related changes in the sAHP in a behaviorally correlated manner. Following completion of the MWM testing, we
used a subset of the same animals described above for electrophysiological studies in hippocampal slices. We obtained highquality intracellular recordings of sAHPs in CA1 pyramidal cells

Figure 3. FKBP1b overexpression in hippocampal neurons reversed spatial memory deficits
in aged F344 rats. A, Path length values for the training trials (T1–T3) on each day across 4
training days. Young-Control, Aged-Control (bilateral AAV-EGFP), and Aged-FKBP1b (bilateral
AAV-FKBP1b) rats all improved across training trials, although there was a trend for AgedControl rats to perform more poorly. B, On the retention probe trial (Day 5, platform removed),
Aged-FKBP1b animals exhibited enhanced memory relative to Aged-Control animals, as indicated by shorter path length ( p ⬍ 0.001) and latency ( p ⬍ 0.01) to reach the platform’s former
location; Aged-FKBP1b rats did not differ from Young-Controls on the retention test. Asterisks
denote a significant difference from Aged-Control. C, No group differences in path length or
latency were observed during the visually cued trial (Day 6), indicating that deficits in sensorimotor function did not account for the differences in retention performance.
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Figure 5. Correlation of sAHP duration with impaired spatial memory in the MWM. Pearson
correlation analysis between MWM performance and averaged sAHPs for individual animals
showed that enhanced spatial memory performance (shorter retention trial path length) was
correlated with reduced sAHP duration and sAHP amplitude (data not shown). Note that there
was very little overlap in sAHP duration between the Aged-FKBP1b group and the Aged-Control
group.

Figure 4. FKBP1b overexpression reversed the age-related augmentation of the sAHP in
hippocampal neurons from the MWM-tested aged animals. A, Representative traces of the
sAHP following a burst of four action potentials elicited by an intracellular current pulse (lower
trace) in hippocampal neurons of an Aged-Control rat (blue) and an Aged-FKBP1b rat (red). B,
sAHP amplitude and duration were substantially greater in neurons from Aged-Control rats
than neurons from Young-Control rats ( p ⬍ 0.0001) or Aged-FKBP1b ( p ⬍ 0.0001) rats, but
did not differ between Aged-FKBP1b and Young-Control rats. Asterisks denote a significant
difference from Aged-Control.

(Fig. 4A) from 18 of the behaviorally characterized animals (13
neurons from five Young-Control rats; 16 neurons from six
Aged-Control rats; and 17 neurons from seven Aged-FKBP1b
rats). These recording studies began 7 d after behavioral testing
ended and continued for ⬃9 weeks, alternating animals from the
different groups.
All cells recorded met standard criteria for healthy neurons,
and no group differences were seen in baseline electrophysiological parameters (Table 1). However, highly significant group differences were found for sAHP amplitude and duration,
regardless of whether individual cells (F(2,43) ⫽ 16.64; p ⬍ 0.0001)
or averaged values per animal (F(2,15) ⫽ 12.89; p ⬍ 0.01) were
used as the statistical population. The sAHPs from Aged-FKBP1b
rats were similar to those from Young-Control rats and substantially smaller than those from Aged-Control rats (Fig. 4 A, B).
This effect was dramatic, as there was little overlap of sAHP magnitudes between the Aged-Control and Aged-FKBP1b groups.
The electrophysiological effects of FKBP1b overexpression were
highly stable across the 9 week recording period, as there was no

difference ( p ⫽ 0.41) in sAHP amplitudes between FKBP1btransduced cells recorded during earlier (1.66 ⫾ 0.29 mV; n ⫽ 9)
versus later (1.34 ⫾ 0.24 mV; n ⫽ 8) phases of the recording
period.
Furthermore, across individual animals, we found significant
positive correlations between the degree of impairment of water
maze memory performance and both sAHP amplitude (r ⫽ 0.51;
p ⬍ 0.05) and sAHP duration (r ⫽ 0.67; p ⬍ 0.01; Fig. 5). Thus,
the FKBP1b intervention shifted both Ca 2⫹-dependent electrophysiology and cognitive performance in aged rats to levels similar to those in young rats, in a correlated manner. This
correlation remained even when the Young-Control group was
omitted from analysis to remove age as a confounding factor
(e.g., without the Young-Control group, correlation of MWM
path length with sAHP duration was r ⫽ 0.62; p ⬍ 0.05).
Simultaneous Ca 2ⴙ imaging and electrophysiological
recording
We then imaged intracellular Ca 2⫹ responses simultaneously
with electrophysiological recordings in a separate cohort of aged
animals (n ⫽ 10) to test the prediction that FKBP1b overexpression should induce effects on coincident Ca 2⫹ transients that
covaried with its effects on Ca 2⫹-dependent sAHPs. In addition,
we measured Ca 2⫹ responses elicited during trains of postsynaptic action potentials generated by 7 Hz RSS of the Schaffer collaterals. With aging, the rise time of this Ca 2⫹ response is
substantially accelerated because of increased RyR-mediated
Ca 2⫹ release from the endoplasmic reticulum (Gant et al., 2006,
2011).
In 10 aged rats, AAV-FKBP1b was injected into one hippocampus and AAV-EGFP into the contralateral hippocampus,
and intracellular responses were measured in hippocampal slices
over a 3 week period beginning ⬃6 weeks after AAV injection.
We obtained concurrent electrophysiology and optical Ca 2⫹ imaging in nine neurons from the AAV-FKBP1b-injected hippocampi and six neurons from the AAV-EGFP control
hippocampi. sAHPs were substantially smaller in the FKBP1btreated neurons (Fig. 6A; amplitude and duration, p ⬍ 0.01;
mean values not shown), essentially replicating the preceding
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Figure 6. FKBP1b overexpression in aged rat neurons reduced Ca 2⫹ transients imaged
simultaneously with the sAHP. A, Representative examples of the sAHPs (top traces) and simultaneously imaged Ca 2⫹ transients (bottom traces) in an Aged-Control neuron and an AgedFKBP1b neuron illustrating that FKBP1b induced a decrease in both responses. Middle trace,
Intracellular current pulse triggering the action potential burst. B, FKBP1b overexpression significantly reduced Peak⌬Ca 2⫹ ( p ⬍ 0.05) and the area under the curve ( p ⬍ 0.001) of the
Ca 2⫹ response during the sAHP. Asterisks indicate a significant difference from Aged-Control.
C, Across individual neurons, the FKBP1b-induced AUC Ca 2⫹ reduction was correlated with the
reduction in the AUC of the sAHP. Red triangles, Aged-FKBP1b; blue circles, Aged-Controls; AUC
Ca 2⫹, %⌬F times seconds; AUC sAHP, millivolts times milliseconds).

sAHP experiment (Fig. 4). Additionally, AAV-FKBP1b significantly reduced the area under the curve of the sAHP ( p ⬍ 0.01).
Optical imaging of the Ca 2⫹ transients coinciding with the
sAHPs showed that AAV-FKBP1b injection significantly reduced
the peak amplitude (%⌬F/F ) and AUC of the Ca 2⫹ transients
compared with AAV-EGFP-injected cells (Fig. 6B; p ⬍ 0.05 and
p ⬍ 0.01, respectively). Moreover, correlation analysis showed
that the AUCs of the Ca 2⫹ responses and sAHPs covaried across
individual neurons (Fig. 6C; r ⫽ 0.57; p ⬍ 0.05).
In addition, the 7 Hz RSS-induced Ca 2⫹ response, the rise
time of which is strongly accelerated by RyR-mediated Ca 2⫹ release (Gant et al., 2006), reached peak levels more slowly in neurons from aged AAV-FKBP1b-injected hippocampi (much as in
neurons from young rats) compared with aged AAV-EGFP con-

Figure 7. FKBP1b overexpression in aged rat neurons slowed the Ca 2⫹ rise associated with
RSS. A, Examples of Ca 2⫹ responses during the first 5 s of RSS of the Schaffer collaterals in
neurons from an Aged-Control and an Aged-FKBP1b rat, illustrating the difference in the rising
time constant (), but not the peak of the response. The bottom trace is a representative
intracellular recording showing the train of action potentials elicited by the 7 Hz synaptic stimulation protocol. B, FKBP1b overexpression significantly reduced the AUC of the RSS Ca 2⫹
response and significantly increased the rising time constant. AUC units of the Ca 2⫹ responses,
%⌬F times seconds. *p ⬍ 0.05 (significant difference from Aged-Control.

trol neurons (increased , p ⬍ 0.05; Fig. 7 A, B). No differences
were observed in peak %⌬Ca 2⫹ during RSS, although the AUC of
the RSS stimulated Ca 2⫹ response was reduced in AAV-FKBP1btreated hippocampal neurons ( p ⬍ 0.05) because of the slower
rise time to peak (Fig. 7B).

Discussion
The present study combines gene transfer approaches, behavioral
assessment, intracellular electrophysiology and simultaneous
Ca 2⫹ imaging to elucidate mechanisms of brain aging-related
neuronal Ca 2⫹ dysregulation and cognitive impairment. We
show, for the first time, that in aged rats in which hippocampal
RyR-mediated Ca 2⫹ transients and the Ca 2⫹-dependent sAHP
are normally increased, hippocampal overexpression of FKBP1b
dramatically reduced these responses, restoring them to levels
found in young rats. Furthermore, this reduction of the sAHP
was significantly correlated with reversal of the spatial memory
impairment characteristically present in aged animals (Fig. 5).
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These data strongly support the novel hypothesis that the deficit in hippocampal CA1 FKBP1b expression/function observed
previously in aging rats (Kadish et al., 2009; Gant et al., 2014) is an
underlying molecular mechanism of brain aging-related Ca 2⫹
dysregulation and cognitive dysfunction. Specifically, our present results satisfy the critical prediction of a mechanistic molecular hypothesis (Falkow, 2004) that selectively counteracting the
proposed pathogenic mechanism (FKBP1b deficit) should substantially lessen or reverse pathologic manifestations. Thus, together with our prior study on the effects of hippocampal
FKBP1b knockdown (Gant et al., 2011), the findings here with
FKBP1b overexpression indicate that FKBP1b is a key regulator
of neuronal Ca 2⫹ homeostasis and provide strong support for an
FKBP1b-deficiency mechanistic hypothesis of unhealthy brain
aging.
Relationship of cognitive impairment to Ca 2ⴙ dysregulation
FKBP1b overexpression reversed both cognitive impairment and
Ca 2⫹ dysregulation, raising the question of whether the reversal
of Ca 2⫹ dysregulation played a causal role in the enhanced cognition. As noted, several prior studies have found close associations between aging-related impairment of cognition/plasticity
and increased sAHP magnitude or LTCC activity in hippocampal
or cortical pyramidal neurons of rabbits, rats, and monkeys (Disterhoft et al., 1996; Thibault and Landfield, 1996; Tombaugh et
al., 2005; Disterhoft and Oh, 2007; Luebke and Amatrudo, 2012).
In addition to those correlational data, it has been shown that
L-type Ca 2⫹ channel blockers and other agents that reduce the
sAHP can improve learning (Disterhoft and Oh, 2006). Furthermore, in the present work, we show that memory performance
remained inversely correlated with sAHP magnitude following a
molecular intervention (FKBP1b overexpression) that significantly reduced the sAHP (Fig. 5) and parallel Ca 2⫹ transients
(Fig. 6). The persistence of this association despite strong modification of the sAHP appears to substantially increase the likelihood of a causal influence of hippocampal Ca 2⫹ responses on
cognitive function.
However, reduction of the sAHP is clearly not the only pathway through which restoration of Ca 2⫹ regulation could have
enhanced learning. Presumably, multiple Ca 2⫹-related processes
in addition to the sAHP were rescued by FKBP1b overexpression,
and normalization of one or more of those might have contributed to enhanced spatial learning. For example, long-term potentiation, a lasting form of synaptic plasticity associated with
learning, is a Ca 2⫹-dependent process shown to be impaired at
some pyramidal cell synapses with aging (Lynch et al., 2006).
Because it depends on dendritic spine cytoskeletal reorganization
mediated by the Ca 2⫹-activated protease calpain (Lynch and
Baudry, 1987; Lynch et al., 2006), excessive Ca 2⫹ transients with
aging could seemingly disrupt finely tuned spine calpain activation, resulting in impaired LTP. Accordingly, one pathway
through which restoration of Ca 2⫹ regulation by FKBP1b might
have enhanced learning is via LTP rescue.
FKBP1b actions on Ca 2ⴙ regulation
FKBPs are immunophilins that bind the immunosuppressant
drugs FK506 and rapamycin and mediate inhibition of immune
response pathways. In addition, FKBPs are characterized by peptidylprolyl isomerase activity and are present in many cell types of
the body. Although FKBPs have diverse functions, including protein folding, protein chaperoning and transcriptional regulation
(Kang et al., 2008), only FKBP1b and its closely related isoform,
FKBP1a/FKBP12, the smallest members of the FKBP protein
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family, are known to importantly regulate Ca 2⫹ in excitable cells.
In myocytes, FKBP1b and FKBP1a bind to and stabilize RyRs in
the closed state, thereby inhibiting Ca 2⫹-induced Ca 2⫹ release
from the sarcoplasmic reticulum. Deletion of FKBP1b in cardiac
cells (or FKBP1a in other myocytes) results in aberrant excitation– contraction coupling and “leaky” RyRs (Zalk et al., 2007;
MacMillan, 2013). Although it has not been known whether the
small FKBPs regulate Ca 2⫹ release in neurons, we found previously that FKBP1b knockdown/disruption in pyramidal neurons
results in an increased sAHP magnitude, faster rise time of the
RSS-induced Ca 2⫹ response, and an increase in plasma membrane LTCC activity (Gant et al., 2011). Conversely, we show here
that FKBP1b overexpression had the opposite effects on these
responses, reducing the sAHP and its parallel Ca 2⫹ transient and
slowing the rise of the RSS-activated Ca 2⫹response. Since sAHP
magnitude and RSS-response rise time are highly dependent on
RyR-mediated Ca 2⫹ release (i.e., are suppressed by ryanodine;
Gant et al., 2006), our data show that, as in myocytes, FKBP1b in
neurons inhibits CICR from RyRs. Additionally, in neurons,
FKBP1b inhibits membrane LTCC activity. Thus, FKBP1b appears
to exert substantial regulatory control over Ca 2⫹-dependent signaling in neurons.
Small FKBPs also inhibit the mammalian target of rapamycin
(mTOR) (Hoeffer et al., 2008; Hausch et al., 2013), an important
regulator of growth and plasticity pathways (Hoeffer and Klann,
2010). In the brain, mTOR is a target of BDNF, which plays major
roles in neural plasticity, neurite outgrowth, and neuroprotection (Lynch et al., 2006; Scharfman and MacLusky, 2006). Although mTOR can apparently modulate Ca 2⫹ release from IP3
receptors in smooth muscle, it is not known to participate in
RyR-mediated Ca 2⫹ release (MacMillan and McCarron, 2009).
Therefore, it appears unlikely that the FKBP–mTOR pathway
contributed significantly to the FKBP1b-induced reductions in
RyR-mediated Ca 2⫹ responses seen in the present study.
Reversibility of Ca 2ⴙ dysregulation and cognitive aging
A particularly striking finding in this study is that major agingrelated changes in hippocampal Ca 2⫹ regulation and spatial
memory could be fully reversed by FKBP1b overexpression at
⬎20 months of age. In rats, detectable alterations in hippocampal
Ca 2⫹-dependent processes (Gant et al., 2006; Lynch et al., 2006)
and MWM memory performance (Markowska, 1999; Kadish et
al., 2009) normally emerge by midlife (⬃12 months old) and are
well established by 20 months of age. Reversibility of learning
deficits in aging animals has also been seen previously in studies
of Ca 2⫹ channel antagonists (Disterhoft and Oh, 2006) and antioxidants (Cartford et al., 2002), among other treatments. This
reversibility of cognitive deficits at late ages seems surprising considering the numerous reports of aging-related structural
changes in brain synapses, axons, and dendrites, many of which
have been correlated with declining cognitive functions (Peters et
al., 1996; Rosenzweig and Barnes, 2003; Masliah et al., 2006; Morrison and Hof, 2007; Scheff et al., 2007). One possible explanation
for reversibility despite morphological alterations may be that the
aging brain compensates for some localized anatomical changes,
but is unable to compensate for a widely acting and fundamental
deficit such as Ca 2⫹ dysregulation. Alternatively, morphological
alterations may be more reversible than is generally recognized
(Morrison and Hof, 2007). Regardless of the reasons, however,
the observations on reversibility may have important translational implications.
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Potential relevance to Alzheimer’s disease
Advanced age is essentially the leading risk factor for AD (Reitz et
al., 2011), suggesting that some processes seen in normal brain
aging increase susceptibility to neurodegeneration and AD. Considerable evidence indicates that one of those processes may be
neuronal Ca 2⫹ dysregulation. Elevated intracellular [Ca 2⫹] induces electrophysiological deterioration of hippocampal neurons (Scharfman and Schwartzkroin, 1989), and elevated Ca 2⫹
release from RyRs is toxic to neurons (Verkhratsky, 2005; Bezprozvanny and Mattson, 2008). Importantly, significant Ca 2⫹
dysregulation is also present in AD, as evidenced by altered calcineurin and calpain activation, modified Ca 2⫹ release, and disturbance of Ca 2⫹ signaling by AD-related pathology (Nixon et
al., 1994; Gibson et al., 1996; Rozkalne et al., 2011; Hudry et al.,
2012; Overk et al., 2014). Furthermore, mouse models of AD
exhibit dysregulated Ca 2⫹ release from RyRs and IP3 receptors,
as well as altered Ca 2⫹ channel activity (Disterhoft and Oh, 2006;
Stutzmann et al., 2006; Thibault et al., 2012; Wang and Mattson,
2014). In vivo Ca 2⫹ imaging in AD model mice also has revealed
elevation of Ca 2⫹ in cortical neuron dendrites, which is more
pronounced in locations proximal to ␤ amyloid plaques
(Kuchibhotla et al., 2008).
In previous microarray studies, we found that hippocampal
FKBP1b gene expression is downregulated in human subjects
with incipient or advanced AD (Blalock et al., 2004) as well as in
normally aging rats (Kadish et al., 2009; Gant et al., 2014). Together with the present results, those findings raise the intriguing
possibility that declining expression of the gene encoding
FKBP1b during normal brain aging might act synergistically or
additively with other sources of pathology to exacerbate Ca 2⫹
dysregulation and increase susceptibility to and/or progression of
AD. Thus, if supported by further studies, the present findings
suggest that cell-specific elevation of FKBP1b expression may be
a feasible new approach for modifying the course of deleterious
brain aging and, possibly, early stage Alzheimer’s disease.
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